Researchers published an open‑source screening platform in Nature Communications that accelerates identification of synergistic drug combinations across cellular models. The platform integrates high‑throughput phenotypic assays, computational scoring of pairwise interactions, and public code to enable reproducible discovery campaigns. Authors report that the framework shortens the timeline from hypothesis to validated combination and lowers barriers for academic groups and smaller companies to run combination screens. The open model aims to democratize combination discovery and could hasten preclinical selection of regimens for oncology and infectious disease.